PremiumRatingsImmunovant’s Promising Clinical Trial Results and Market Dynamics Drive Buy Rating Immunovant’s Batoclimab Shows Promising Efficacy in MG and CIDP, Justifying Buy Rating Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright PremiumThe FlyBiohaven price target lowered to $57 from $73 at Bernstein Immunovant initiated with a Hold at Jefferies Immunovant’s Promising Pipeline and Strategic Focus Drive Buy Rating PremiumRatingsImmunovant’s Strategic Positioning and Financial Strength Propel IMVT-1402 Towards Pivotal Studies Immunovant management to meet with Piper Sandler Immunovant Reports Progress Amid Increased R&D Costs 
